围产期心肌病患者后续妊娠的全球ESC注册研究
该研究基于全球ESC围产期心肌病注册(2012–2023),分析73名患者的98次后续妊娠。26%的后续妊娠因治疗性终止、流产或死胎而提前结束;20%发生临床恶化,2%发生孕产妇全因死亡。基线左室射血分数(LVEF)≥50%者LVEF显著下降,可能与心衰药物使用减少有关。
要点
- 后续妊娠中临床恶化 composite 发生率为20%,孕产妇全因死亡率为2%。
- 基线LVEF<50%未增加不良母体结局频率,且该组LVEF未见进一步下降。
- 基线LVEF≥50%者LVEF显著下降,可能与妊娠及产后心衰药物使用减少有关。
核心结论
- 母体发病率和死亡率低于预期。
- 基线LVEF<50%与不良母体结局增加无关,且该组LVEF未见进一步下降。
- 基线LVEF≥50%的后续妊娠者LVEF下降,可能与心衰药物治疗减少有关。
- 约五分之一病例进行了治疗性终止。
- 可考虑将伴持续轻度左室功能受损的后续妊娠从mWHO IV类(禁忌)重新分类为mWHO III类,但需在有经验的医疗团队照护下并给予适当药物治疗。
研究设计与样本
- 全球欧洲心脏病学会围产期心肌病注册(2012–2023)的子研究。
- 从332例围产期心肌病患者中,73名女性共98次后续妊娠。
- 报告母体与新生儿结局。
主要发现
- 25次(26%)后续妊娠提前结束,其中治疗性终止20/25、流产4/25、死胎1/25。
- 后续妊娠结束后的中位随访时间为198天(四分位距160–240)。
- 后续妊娠前26%患者LVEF持续降低至<50%,仅6% LVEF<40%。
- 临床恶化(全因死亡、心血管再住院或LVEF下降≥10个百分点且<50%的复合终点)发生于20%的后续妊娠,孕产妇全因死亡率为2%。
- 心衰症状/体征和NYHA分级恶化分别发生于26%和22%的后续妊娠;随访时平均LVEF为50%(±12%),69%的后续妊娠LVEF≥50%。
关键数值与推荐
- 临床恶化复合终点:全因死亡、心血管再住院或LVEF下降≥10个百分点且<50%。
- 后续妊娠前LVEF持续降低至<50%者占26%,LVEF<40%者占6%。
- 随访时平均LVEF为50%(±12%),69%的后续妊娠LVEF≥50%。
- mWHO IV类(禁忌)可考虑重新分类为mWHO III类(需有经验团队照护和适当药物治疗)。
临床怎么用
- 后续妊娠前应评估LVEF,基线LVEF≥50%者仍需警惕LVEF下降。
- 妊娠及产后心衰药物治疗减少可能与LVEF下降有关,需优化药物治疗管理。
- 伴持续轻度左室功能受损的后续妊娠可考虑从mWHO IV类调整为III类,但需在有经验团队照护下进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The risk of heart failure progression or mortality in patients with peri-partum cardiomyopathy (PPCM) during subsequent pregnancies (SSPs) is a significant concern for patients, their families, and healthcare providers. However, there is limited contemporary, prospective data on SSP outcomes in PPCM patients from diverse ethnic and sociodemographic groups. This study aimed to assess maternal and neonatal outcomes in PPCM patients undergoing SSPs. METHODS: This is a sub-study on PPCM and SSPs of the global European Society of Cardiology PPCM Registry that recruited patients from 2012 to 2023. Maternal and neonatal outcomes were reported. RESULTS: From 332 patients with PPCM, there were 98 SSPs among 73 women. Of these, 25 (26%) SSPs ended prematurely due to therapeutic termination (20/25), miscarriage (4/25), and stillbirth (1/25). The median follow-up from the end of the SSP was 198 days (inter-quartile range 160-240). Left ventricular ejection fraction (LVEF) was persistently reduced to <50% prior to the SSP in 26% of patients, with only 6% having an LVEF <40%. Patient characteristics were similar, irrespective of SSP baseline LVEF. Clinical worsening [composite of all-cause death, cardiovascular rehospitalization, or decline in LVEF ≥10% (percentage points) and to <50%] occurred in 20% SSPs, with 2% all-cause maternal mortality. Signs/symptoms of heart failure and worsening of New York Heart Association class occurred in 26% and 22% of SSPs, respectively. At follow-up, the mean LVEF was 50% (±12%), and in 69% of SSPs, the LVEF was ≥50%. African women had similar outcome as the other ethnic groups. Pre-term delivery occurred in 24% of SSPs, 20% of babies were of low birth weight, and there was 3% all-cause neonatal mortality. Compared with women with SSP baseline LVEF <50%, fewer women with LVEF ≥50% were on heart failure pharmacotherapies prior to the SSP, and in this group of women, there was a significant decline in LVEF. CONCLUSIONS: Maternal morbidity and mortality rates were lower than anticipated. Baseline LVEF <50% was not associated with an increased frequency of adverse maternal outcomes, and no further decline in LVEF was observed in this group. In contrast, women with SSPs and a baseline LVEF ≥50% experienced a decline in LVEF, potentially attributable to reduced use of heart failure pharmacotherapy during pregnancy and the post-partum period. Therapeutic termination was performed in approximately a fifth of cases. The findings suggest that reclassification of a SSP with persisting mild left ventricular impairment from modified World Health Organization (mWHO) Class IV (contraindicated) to mWHO III may be considered, while remaining under the care of an experienced medical team and with appropriate pharmacological management.
引用
- Sliwa K, Jackson A, Viljoen C, et al. Pregnancies in women after peri-partum cardiomyopathy: the global European Society of Cardiology EuroObservational Research Programme Peri-Partum Cardiomyopathy Registry. Eur Heart J. 2025. PMID: 39936475. doi:10.1093/eurheartj/ehaf006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。